Skip to main content

Table 4 Demographics and clinical characteristics stratified by infection outcomes in the per-protocol study population

From: Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial

 

No infection

N = 475 (98.1%)

Infection

N = 9 (1.9%)

All

N = 484

P value

Demographics

 Age, mean ± SD, (range), years

62.5 ± 9.0 (33–88)

63.4 ± 6.5 (48–71)

62.5 ± 9.0 (48–71)

0.75

 Race, n (%)

   

1.0

  White

351 (73.9)

8 (88.9)

359 (74.2)

 

  Black

77 (16.2)

1 (11.1)

78 (16.1)

 

  Hispanic

27 (5.7)

0 (0.0)

27 (5.6)

 

  Other

20 (4.2)

0 (0.0)

20 (4.1)

 

Clinical characteristics

 Biopsy result, n (%)

   

0.609

  Negative

241 (50.7)

4 (44.4)

245 (50.6)

 

  Prostate cancer

185 (38.9)

5 (55.6)

190 (39.3)

 

  HGPIN

49 (10.3)

0 (0.0)

49 (10.1)

 

 History of urinary tract infection, n (%)

   

0.029

  Yes

50 (10.5)

3 (33.3)

53 (10.9)

 

  No

414 (87.2)

5 (55.6)

419 (86.6)

 

  Unknown/missing

11 (2.3)

1 (11.1)

12 (2.5)

 

 History of urinary retention; n (%)

   

0.511

  Yes

38 (8.0)

1 (11.1)

39 (8.1)

 

  No

387 (81.5)

8 (88.9)

395 (81.6)

 

  Unknown/missing

50 (10.5)

0 (0.0)

50 (10.3)

 

 FQ usage in prior 2 years, n (%)

   

0.681

  Yes

109 (22.9)

3 (33.3)

112 (23.1)

 

  No

254 (53.5)

4 (44.4)

258 (53.3)

 

  Unknown/Missing

112 (23.6)

2 (22.2)

114 (23.6)

 

 Hospitalized in prior 1 year; n (%)

   

0.388

  Yes

44 (9.3)

2 (22.2)

46 (9.5)

 

  No

418 (88.0)

7 (77.8)

425 (87.8)

 

  Unknown/missing

13 (2.7)

0 (0.0)

13 (2.7)

 

 Healthcare worker; n (%)

   

0.710

  Yes

16 (3.4)

0 (0.0)

16 (3.3)

 

  No

406 (85.5)

9 (100.0)

415 (85.7)

 

  Unknown/missing

53 (11.2)

0 (0.0)

53 (11.0)

 

 Charlson comorbidity score; n (%)

   

0.144

  0

387 (81.5)

6 (66.7)

393 (81.2)

 

  1

16 (3.4)

1 (11.1)

17 (3.5)

 

  2

35 (7.4)

0 (0.0)

35 (7.2)

 

  3–16

37 (7.8)

2 (22.2)

39 (8.1)

 
  1. Abbreviations: HGPIN high-grade prostatic intraepithelial neoplasia, FQ fluoroquinolone